There are currently 64 active clinical trials seeking participants for Metastatic Breast Cancer research studies. The states with the highest number of trials for Autism participants are Texas, California, Florida and New York.
STUDY02001740;22SCH740: Estradiol For ER+ Advanced Breast Cancer (ESTHER)
NCT05716516
Recruiting
Determine whether subjects harboring ESR1-mutant/amplified breast cancer have a higher rate of clinical benefit from 17b-estradiol therapy than subjects with ESR1-wild-type breast cancer
Gender:
Female
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Metastatic Breast Cancer
Register for Updates
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer
NCT05216432
Recruiting
This is an open-label, FIH study designed to evaluate the maximum tolerated dose, recommended Phase 2 dose, safety, tolerability, PK, pharmacodynamics, and preliminary antineoplastic activity of RLY-2608, in advanced solid tumor patients with a Phosphatidylinositol-4,5-bisphosphate-3 kinase, catalytic subunit alpha (PIK3CA) mutation in blood and/or tumor per local assessment. The study will evaluate RLY-2608 as a single agent for patients with unresectable or metastatic solid tumors, RLY-2608 +... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/07/2023
Locations: The University of Arizona Cancer Center, Tucson, Arizona +20 locations
Conditions: PIK3CA Mutation, Solid Tumor, Adult, HER2-negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Unresectable Solid Tumor
Register for Updates
Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib
NCT06083038
Recruiting
This is a prospective, descriptive, single site, observational study in subjects receiving alpelisib for treatment of metastatic breast cancer. The purpose of the study is to characterize the impact of alpelisib on glucose control in patients with breast cancer using continuous glucose monitoring to measure glucose levels throughout the day and night. Patients will follow a hyperglycemia prevention and management regimen aimed to diminish hyperglycemia known to occur in most oncology patients st... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
10/16/2023
Locations: HealthPartners Cancer Research Center, Saint Louis Park, Minnesota
Conditions: Metastatic Breast Cancer
Register for Updates
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT04683679
Recruiting
The purpose of this study is to find out whether adding pembrolizumab, with or without olaparib, to standard radiation therapy is a safe and effective treatment for metastatic breast cancer, , and to see whether the study treatment is better than, the same as, or worse than the usual approach (radiation therapy alone).
Gender:
Female
Ages:
18 years and above
Trial Updated:
10/04/2023
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations
Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Register for Updates
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
NCT04030507
Recruiting
This research study is studying the usefulness of magnetic resonance imaging (MRI) to screen for brain metastases (spread of the breast cancer to the brain).
Gender:
All
Ages:
18 years and above
Trial Updated:
09/21/2023
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Inflammatory Breast Cancer, Metastatic Breast Cancer
Register for Updates
Dignity, Legacy, Advocacy, and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community
NCT05314179
Recruiting
The proposed program, "Doulas - AC" will provide Dignity, Legacy, Advocacy and Support for Advanced Cancer: Reimagined End of Life Care in the Black Community." The goals are to: 1) provide a community-based, trained companion to journey alongside the patient with advanced cancer, 2) to help the individual explore meaning and create legacy, 3); offer support and navigation for practical needs of illness (e.g., financial assistance for food and housing, accessing and affording medications, transp... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
09/06/2023
Locations: UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania
Conditions: Metastatic Breast Cancer
Register for Updates
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT05826964
Recruiting
The majority of patients (pts) with breast cancer have hormone receptor positive (HR+) disease, and this holds true for pts with advanced breast cancer (ABC). Currently frontline therapy for pts with HR+ ABC is antihormonal therapy with an aromatase inhibitor or selective estrogen receptor degrader plus a CDK4/6i. The proposed trial is a randomized study to further evaluate the potential benefit of switching a frontline regimen at the time that a molecular signal, ctDNA, suggests progression pri... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/16/2023
Locations: University of Miami, Miami, Florida
Conditions: Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
Register for Updates
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT05534438
Recruiting
The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an effective treatment for people with oligometastatic breast cancer. Participants will stay on their usual drug therapy while they receive SBRT. This combination of SBRT to a single metastatic site and usual drug therapy may prevent participants' cancer from worsening in other metastatic sites or spreading.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/03/2023
Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +7 locations
Conditions: Oligometastatic Breast Carcinoma, Breast Cancer, Metastatic Breast Cancer, Metastatic Breast Carcinoma, ER+ Breast Cancer, HER2+ Breast Cancer
Register for Updates
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT03449238
Recruiting
Patients with metastatic breast cancer with at least 2 brain metastases will receive pembrolizumab every 3 weeks. Patients will undergo stereotactic radiosurgery (SRS) to one of the brain lesions. Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
Gender:
Female
Ages:
Between 19 years and 90 years
Trial Updated:
06/29/2023
Locations: Weill Cornell Medicine, New York, New York +2 locations
Conditions: Metastatic Breast Cancer, Brain Metastases
Register for Updates
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT05524584
Recruiting
This is a phase 2, open-label, singled-arm clinical trial determining efficacy of combination therapy with anastrozole, fulvestrant and abemaciclib in subjects with breast cancer. These are subjects who are newly diagnosed advanced or metastatic hormone receptor positive breast cancer or subjects who have progressed following treatment free interval of more than 12 months following adjuvant or neoadjuvant treatment.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/23/2023
Locations: Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California
Conditions: Breast Cancer, Metastatic Breast Cancer, Hormone Receptor-positive Breast Cancer, HER2-negative Breast Cancer
Register for Updates
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
NCT05207709
Recruiting
HARMONIA is an international, multicenter, randomized, open-label and phase III study. The primary objective of this study is to demonstrate that the combination of ribociclib with endocrine therapy (letrozole or fulvestrant) is superior to palbociclib with endocrine therapy (letrozole or fulvestrant) in prolonging progression-free survival in patients with advanced HR+/HER2- and HER2-E breast cancer. The study will enroll approximately 456 patients with HER2-E disease from approximately 95 site... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2023
Locations: Carle Cancer Center, Urbana, Illinois +51 locations
Conditions: Metastatic Breast Cancer
Register for Updates
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
NCT04020575
Recruiting
Phase I/II study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express either a chimeric antigen receptor, huMNC2-CAR44 or huMNC2-CAR22, which are specific for a cleaved form of MUC1 (MUC1*).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/15/2023
Locations: City of Hope Medical Center, Duarte, California
Conditions: Metastatic Breast Cancer
Register for Updates